Meltem Ocak

Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer

Levent Kabasakal, Mohammad Abuqbeitah, Aslan Aygün et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2015 · 206 citations

Normal Organs, Urology, Oncology +8

Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours

Levent Kabasakal, Emre Demirci, Meltem Ocak et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2012 · 156 citations

Positron Emission Tomography, Neuroendocrine Tumours, Oncologic Imaging +13

Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging

Emre Demirci, Onur Erdem Şahin, Meltem Ocak et al. · Nuclear Medicine Communications · 2016 · 155 citations

68Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma

Emre Demirci, Meltem Ocak, Levent Kabasakal et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2014 · 140 citations

Positron Emission Tomography, Urology, Engineering +9

Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging

Levent Kabasakal, Emre Demirci, Meltem Ocak et al. · Nuclear Medicine Communications · 2015 · 135 citations